Vande Catsyne, C.-A., Sayyed, S. A., Molina Ortiz, P., Moës, B., Communi, D., Muller, J., Heusschen, R., CAERS, J., Azzi, A., Erneux, C., & Schurmans, S. (2020). Altered chondrocyte differentiation, matrix mineralization and MEK-Erk1/2 signaling in an INPPL1 catalytic knock-out mouse model of opsismodysplasia. Advances in Biological Regulation, 76, 100651. doi:10.1016/j.jbior.2019.100651 Peer Reviewed verified by ORBi |
Heusschen, R., Muller, J., Duray, E., WITHOFS, N., Bolomsky, A., Baron, F., Beguin, Y., Menu, E., Ludwig, H., & Caers, J. (2018). Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leukemia and Lymphoma, 59, 14-28. doi:10.1080/10428194.2017.1323272 Peer Reviewed verified by ORBi |
Bolomsky, A., Heusschen, R., Schlangen, K., Stangelberger, K., Muller, J., Schreiner, W., Zojer, N., Caers, J., & Ludwig, H. (2018). Maternal embryonic leucine zipper kinase is a novel target for proliferation associated high-risk myeloma. Haematologica, 103, 325-335. doi:10.3324/haematol.2017.172973 Peer Reviewed verified by ORBi |
Heusschen, R., Bolomsky, A., Schlangen, K., Schonfelder, K., Muller, J., Shreiner, W., Zojer, N., CAERS, J., & Ludwig, H. (February 2017). Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma and its associated Bone Disease [Paper presentation]. 32nd General Annual Meeting of the Belgian Hematological Society. |
Heusschen, R., Muller, J., WITHOFS, N., BARON, F., BEGUIN, Y., & CAERS, J. (2017). Multiple myeloma bone disease: from mechanisms to next generation therapy. Belgian Journal of Hematology, 8, 66-74. Peer Reviewed verified by ORBi |
Heusschen, R., Muller, J., Bolomsky, A., Schonfelder, K., Plougonven, E., Léonard, A., BEGUIN, Y., Cohen-Solal, M., Heinz, L., & CAERS, J. (2017). Maternal Embryonic Leucine Zipper Kinase (MELK) inhibition has direct effects on bone cells and prevents the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 44th Annual European Calcified Tissue Society Congress. |
Heusschen, R., Muller, J., Bolomsky, A., Ludwig, H., & CAERS, J. (2017). Maternal Embryonic Leucine Zipper Kinase (MELK) is a key player and an attractive novel target in proliferation-associated high risk multiple myeloma [Paper presentation]. Meeting of the Austrian Society for Hematology and Oncology 2017. |
Muller, J., BINSFELD, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2017). Galectin-1 decreases during osteoclast formation [Poster presentation]. 44th Annual European Calcified Tissue Society Congress, Austria. |
Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (28 February 2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 2nd Herbert Fleisch Workshop, Brugge, Belgium. |
Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology. Peer Reviewed verified by ORBi |
Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy. |
Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy. |
Binsfeld, M., Muller, J., Lamour, V., De Veirman, K., De Raeve, H., Bellahcene, A., Van Valckenborgh, E., BARON, F., BEGUIN, Y., CAERS, J., & Heusschen, R. (2016). Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget, 7, 37931-37943. doi:10.18632/oncotarget.9270 Peer Reviewed verified by ORBi |
Heusschen, R., Muller, J., BEGUIN, Y., Poirier, F., Cohen-Solal, M., Thijssen, V., & CAERS, J. (2016). Galectin-1 attenuates bone resorption by osteoclasts [Poster presentation]. EMBO Workshop: Transducing glycan information into function: Lessons from galectins. |
Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. GIGA day 2016, Liège, Belgium. |
Bolomsky, A., Heusschen, R., Schlangen, K., Schönfelder, K., Muller, J., Schreiner, W., Zojer, N., CAERS, J., & Ludwig, H. (2016). Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma. Blood. Peer Reviewed verified by ORBi |
CAERS, J., de Larrea, C., Leleu, X., Heusschen, R., Zojer, N., Decaux, O., Kastritis, E., Minnema, M., Jurczyszyn, A., Beguin, Y., Wäsch, R., Palumbo, A., Dimopoulos, M., Mateos, M. V., Ludwig, H., & Engelhardt, M. (2016). The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist, 21, 333-342. doi:10.1634/theoncologist.2015-0303 Peer Reviewed verified by ORBi |
Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Brussels, Belgium. |
Heusschen, R., Muller, J., Fillet, M., Vanderkerken, K., Thijssen, V., Cohen-Solal, M., BEGUIN, Y., & CAERS, J. (2016). Lectin-glycoprotein interactions in the diagnosis and biology of myeloma-related bone disease [Poster presentation]. 2nd Herbert Fleisch Workshop of the International Bone and Mineral Society, Brugge, Belgium. |
Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood. Peer Reviewed verified by ORBi |
Thijssen, V., Heusschen, R., CAERS, J., & Griffioen, A. (2015). Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochimica et Biophysica Acta. Reviews on Cancer, 1855 (2), 235-47. doi:10.1016/j.bbcan.2015.03.003 Peer Reviewed verified by ORBi |
Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood, 126 (23), 3018. Peer Reviewed verified by ORBi |
Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., Beguin, Y., Heusschen, R., & CAERS, J. (2015). The anti-angiogenic peptide Anginex blocks osteoclastogenesis. Belgian Journal of Hematology, Abstracts book. Peer Reviewed verified by ORBi |
Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma [Poster presentation]. 57th ASH Annual Meeting and Exposition, Orlando, United States - Florida. |
Binsfeld, M., Beguin, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Heusschen, R., Drion, P., Zilberberg, J., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE, 113764. doi:10.1371/journal.pone.0113764 Peer Reviewed verified by ORBi |
Binsfeld, M., Fostier, K., Muller, J., Baron, F., Schots, R., Beguin, Y., Heusschen, R., & CAERS, J. (2014). Cellular immunotherapy in multiple myeloma : lessons from preclinical models. Biochimica et Biophysica Acta. Reviews on Cancer, 1846, 392-404. doi:10.1016/j.bbcan.2014.08.001 Peer Reviewed verified by ORBi |
Heusschen, R., Schulkens, I., Muller, J., Griffioen, A., BEGUIN, Y., Thijssen, V., & CAERS, J. (2014). Galectins in cancer: jacks of all trades [Paper presentation]. 19th World Congress on Advances in Oncology, Athens, Greece. |
Heusschen, R., Muller, J., Binsfeld, M., Thijssen, V., BEGUIN, Y., & CAERS, J. (2014). Galectin expression in the multiple myeloma microenvironment [Poster presentation]. GIGA day 2014, Liège, Belgium. |
Heusschen, R.* , Schulkens, I.* , van Beijnum, J., Griffioen, A., & Thijssen, V. (2014). Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1842 (2), 284-92. doi:10.1016/j.bbadis.2013.12.003 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46. Peer reviewed |
Heusschen, R., Schulkens, I., Muller, J., Griffoen, A., Beguin, Y., Thijssen, V., & CAERS, J. (2014). Galectins in cancer: jacks of all trades. International Journal of Molecular Medicine. Peer Reviewed verified by ORBi |
Schulkens, I.* , Heusschen, R.* , Van den boogaart, V., van Suylen, R.-J., Dingemans, A., Griffioen, A., & Thijssen, V. (2014). Galectin Expression Profiling Identifies Galectin-1 and Galectin-9Δ5 as Prognostic Factors in Stage I/II Non-Small Cell Lung Cancer. PLoS ONE, 9 (9), 107988. doi:10.1371/journal.pone.0107988 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Binsfeld, M., Heusschen, R., Lamour, V., Van Valckenborgh, E., Bellahcene, A., Baron, F., BEGUIN, Y., & CAERS, J. (2014). Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines. Belgian Journal of Hematology. |
Muller, J., CAERS, J., Binsfeld, M., Dubois, S., Carmeliet, G., BEGUIN, Y., & Heusschen, R. (2014). Galectin expression in the multiple myeloma microenvironment. Belgian Journal of Hematology. Peer Reviewed verified by ORBi |
Heusschen, R., Griffioen, A., & Thijssen, V. (2013). Galectin-9 in tumor biology: a jack of multiple trades. Biochimica et Biophysica Acta. Reviews on Cancer, 1836 (1), 177-85. doi:10.1016/j.bbcan.2013.04.006 Peer Reviewed verified by ORBi |
Heusschen, R. (2013). The role of galectins in the vasculature [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/161190 |
Heusschen, R.* , Freitag, N.* , Tirado-Gonzalez, I., Barrientos, G., Moschansky, P., Munoz-Fernandez, R., Leno-Duran, E., Klapp, B., Thijssen, V., & Blois, S. (2013). Profiling lgals9 splice variant expression at the fetal-maternal interface: implications in normal and pathological pregnancy. Biology of Reproduction, 88 (1), 22. doi:10.1095/biolreprod.112.105460 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Heusschen, R., De Bree, M., Griffioen, A., & Thijssen, V. (2011). Identification and characterization of novel galectin-9 splice variants in endothelial cells [Poster presentation]. 102nd annual meeting of the American Association for Cancer Research, Orlando, United States - Florida. |
Heusschen, R., De Bree, M., Griffioen, A., & Thijssen, V. (2011). Identification and characterization of novel galectin-9 splice variants in endothelial cells. Cancer Research. Peer Reviewed verified by ORBi |
Heusschen, R., Griffioen, A., & Thijssen, V. (2011). The role of galectin-9 splice variants in endothelial cells [Paper presentation]. Annual OOA Retreat, Texel, Netherlands. |
Heusschen, R., De Bree, M., Griffioen, A., & Thijssen, V. (2011). Galectin-9 splice variants in endothelial cells: identification of novel variants and functional characterization. Angiogenesis. Peer Reviewed verified by ORBi |
Heusschen, R., De Bree, M., Griffioen, A., & Thijssen, V. (2011). Galectin-9 splice variants in endothelial cells: identification of novel variants and functional characterization [Paper presentation]. International Meeting on Angiogenesis, Amsterdam, Netherlands. |
Heusschen, R., van Gink, M., Griffioen, A., & Thijssen, V. (2010). MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. Biochimica et Biophysica Acta. Reviews on Cancer, 1805, 87-96. doi:10.1016/j.bbcan.2009.09.005 Peer Reviewed verified by ORBi |